These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36524683)

  • 1. Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor.
    Marro M; Petit AF; Falaise C; Roche M; Gensollen S; Hezard N; Boucekine M; Auquier P; Chambost H; Saultier P
    Haemophilia; 2023 Jan; 29(1):397-400. PubMed ID: 36524683
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 9. Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India.
    Bansal S; Donners AAMT; Fischer K; Kshirsagar S; Rangarajan S; Phadke V; Mhatre S; Sontate B; Silva M; Ansari S; Shetty S
    Haemophilia; 2023 May; 29(3):931-934. PubMed ID: 37029771
    [No Abstract]   [Full Text] [Related]  

  • 10. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.
    Mancuso ME; Mahlangu J; Sidonio R; Trask P; Uguen M; Chang T; Shima M; Young G; Oldenburg J; von Mackensen S
    Haemophilia; 2020 Nov; 26(6):1009-1018. PubMed ID: 33084175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII replacement is still the standard of care in haemophilia A.
    Aledort L; Mannucci PM; Schramm W; Tarantino M
    Blood Transfus; 2019 Nov; 17(6):479-486. PubMed ID: 31846611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 14. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of emicizumab in acquired hemophilia A.
    Poston J; Kruse-Jarres R
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):24-30. PubMed ID: 38066880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors.
    Escobar M; Bullano M; Mokdad AG; Caicedo J; Schultz BG; Fan Q; Verma S
    Expert Rev Hematol; 2023 Jun; 16(6):467-474. PubMed ID: 37114481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.